[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 22 of about 22
1. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK, North American Neuroendocrine Tumor Society (NANETS): The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas; 2010 Aug;39(6):799-800
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
  • Extrapulmonary poorly differentiated neuroendocrine carcinomas can originate in the gastrointestinal tract, bladder, cervix, and prostate.
  • They are infrequently associated with secretory hormonal syndromes (such as the carcinoid syndrome) and rarely express somatostatin receptors.Most poorly differentiated neuroendocrine carcinomas are locally advanced or metastatic at presentation.
  • First-line systemic chemotherapy with a platinum agent (cisplatin or carboplatin) and etoposide is recommended for most patients with metastatic-stage disease; however, response durations are often short.
  • In patients with localized tumors undergoing surgical resection, adjuvant treatment (chemotherapy with or without radiation) is warranted in most cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Jul 15;20(14):3054-60 [12118018.001]
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1720-6 [15150595.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Virchows Arch. 1995;425(6):547-60 [7697211.001]
  • [Cites] World J Surg. 1996 Feb;20(2):132-41 [8661808.001]
  • [Cites] Ann Oncol. 1996 Apr;7(4):365-71 [8805928.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1366-72 [9338459.001]
  • [Cites] J Clin Oncol. 2006 May 1;24(13):2038-43 [16648503.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5441-7 [17135646.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1068-76 [17614337.001]
  • [Cites] Am J Surg Pathol. 2008 May;32(5):719-31 [18360283.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3063-72 [18565894.001]
  • [Cites] Cancer Treat Rev. 2009 May;35(3):228-36 [19068273.001]
  • [Cites] Hum Pathol. 2009 Sep;40(9):1262-8 [19368957.001]
  • [Cites] BMC Cancer. 2001;1:5 [11432756.001]
  • (PMID = 20664477.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA093401-05; United States / NCI NIH HHS / CA / CA093401-01A2; United States / NCI NIH HHS / CA / K23 CA093401-01A2; United States / NCI NIH HHS / CA / K23 CA093401-04; United States / NCI NIH HHS / CA / CA093401-03; United States / NCI NIH HHS / CA / K23 CA093401-02; United States / NCI NIH HHS / CA / CA093401-02; United States / NCI NIH HHS / CA / CA093401-04; United States / NCI NIH HHS / CA / K23 CA093401; United States / NCI NIH HHS / CA / K23 CA093401-03; United States / NCI NIH HHS / CA / K23 CA093401-05
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS286321; NLM/ PMC3100733
  •  go-up   go-down


2. Demirkan B, Unek IT, Eriksson B, Akarsu M, Durak H, Sağol O, Obuz F, Binicier C, Füzün M, Alakavuklar M: A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report. Turk J Gastroenterol; 2009 Sep;20(3):214-9
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with nonfunctional pancreatic neuroendocrine tumor and incidental metachronous colon carcinoma detected by positron emission tomography: case report.
  • Pancreatic neuroendocrine tumors constitute about 2% of all gastrointestinal neoplasms.
  • Due to lack of specific symptoms, most patients with nonfunctional pancreatic neuroendocrine tumors present with locally advanced or metastatic disease.
  • Colon carcinoma ranks third in frequency among primary sites of cancer in both men and women in western countries.
  • Presence of a metachronous colon adenocarcinoma in a patient with nonfunctional pancreatic neuroendocrine tumor has not been reported before.
  • We present a patient who had an asymptomatic mass in the head of the pancreas, detected by ultrasonography in 1996.
  • In 2002, after the diagnosis of an unresectable, nonfunctional pancreatic neuroendocrine tumor, interferon alpha- 2b and octreotide were started.
  • A year after biological treatment, he refused further treatment.
  • In 2004, during the evaluation of dissemination of the asymptomatic disease, positron emission tomography revealed a high uptake by the descending colon despite the failure of other imaging methods.
  • After surgery for operable colon carcinoma, the patient received chemotherapy and biological therapy for both tumors.
  • Since 2005, he has been doing well without any further treatment thus far.
  • In conclusion, computerized tomography/magnetic resonance imaging and octreotide scintigraphy may be insufficient to show disseminated disease and asymptomatic second primary malignancies.
  • Therefore, positron emission tomography is a valuable promising option for the evaluation of gastroenteropancreatic neuroendocrine tumors and concomitant or metachronous malignancies.
  • Lifelong follow-up by a multidisciplinary oncology team is needed so that a long-term survival can be achieved with integrated multimodal systemic treatment approaches.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Colonic Neoplasms / radionuclide imaging. Neoplasms, Second Primary / radionuclide imaging. Neuroendocrine Tumors / radionuclide imaging. Pancreatic Neoplasms / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Pancreatic islet cell tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19821205.001).
  • [ISSN] 2148-5607
  • [Journal-full-title] The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
  • [ISO-abbreviation] Turk J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


3. Valdés Olmos RA, Hoefnagel CA, Bais E, Boot H, Taal B, de Kraker J, Vote PA: [Therapeutic advances of nuclear medicine in oncology]. Rev Esp Med Nucl; 2001 Dec;20(7):547-57

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapeutic advances of nuclear medicine in oncology].
  • With the development of new radiopharmaceuticals there is a tendency to apply nuclear medicine therapy for malignancies of higher incidence (lymphoma, prostate) than the ones which have been treated for many years (thyroid cancer, neuroendocrine tumours).
  • One of the most important areas of current development in radionuclide cancer therapy is the monotherapeutic use of new or already available radiopharmaceuticals in preclinical or phase I studies and to a lesser degree in phase II trials.
  • In this context, the radioimmunotherapy is showing important advances in the treatment of medullary thyroid carcinoma, malignant lymphomas en brain tumours with potential extension to neuroblastoma therapy.
  • The development of DOTA as a chelating agent has lead to the use of Y-90-DOTATOC in the treatment of neuroendocrine tumours, particularly carcinoid tumours, and non-I131I-avid thyroid carcinomas.
  • In an effort to improve tumour targeting together with simultaneous reduction of physiological organ uptake, 131I-MIBG is being used in combination with interferon a and pre-targeting with unlabelled MIBG in the treatment of carcinoid tumours.
  • New routes of administration of radiopharmaceuticals (intratumoral, intra-arterial) have enhanced the treatment of malignancies of liver, pancreas and brain as well as the potential use of radioimmunotherapy by intravesical administration for bladder carcinoma.
  • Another significant tendency in radionuclide therapy is its evolution from monotherapy towards a combined application with other anticancer modalities.
  • Some recent examples of combined therapy with demonstrated anti-tumour effect are found in neuroblastoma (131I-MIBG and chemotherapy), bone metastases of prostatic carcinoma (addition of 89Sr to chemotherapy schedules), brain malignancies (adjuvant use of radioimmnunotherapy in relation to surgery and external radiotherapy) and lymphoma (radioimmunotherapy combined with chemotherapy or immunotherapy).
  • [MeSH-minor] 3-Iodobenzylguanidine / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Brain Neoplasms / radionuclide imaging. Carcinoma / radionuclide imaging. Carcinoma / secondary. Carcinoma, Medullary / radionuclide imaging. Clinical Trials, Phase I as Topic. Clinical Trials, Phase II as Topic. Combined Modality Therapy. Humans. Hyperbaric Oxygenation. Iodine Radioisotopes / administration & dosage. Iodine Radioisotopes / therapeutic use. Liver Neoplasms / radionuclide imaging. Lymphoma / radionuclide imaging. Lymphoma / therapy. Neoplasms / diagnosis. Neoplasms / radiotherapy. Neoplasms / therapy. Neuroblastoma / radionuclide imaging. Neuroblastoma / radiotherapy. Radioimmunotherapy. Radiopharmaceuticals / therapeutic use. Thyroid Neoplasms / radionuclide imaging. Thyroid Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11709141.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 0 / Radiopharmaceuticals; 35MRW7B4AD / 3-Iodobenzylguanidine
  • [Number-of-references] 56
  •  go-up   go-down


Advertisement
4. Miglani A, Kar P: Neuroendocrine tumors of the pancreas. Trop Gastroenterol; 2006 Jan-Mar;27(1):4-10
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors of the pancreas.
  • Pancreatic Neuroendocrine tumors (PNET) are rare tumors that require a high degree of suspicion for timely diagnosis.
  • The severity of symptoms and pace of disease should dictate therapy.
  • Surgical extirpation remains the only curative modality for localized disease, but palliation of hormone-related symptoms can be achieved with different modalities (Management of hormonal Excess, biologic therapy, chemotherapy and biochemotherapy, local-regional therapy with hepatic arterial embolization).
  • [MeSH-major] Carcinoma, Islet Cell. Insulinoma. Pancreatic Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910053.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 41
  •  go-up   go-down


5. Nomura S, Togawa A, Kaiho T, Shinmura K, Yanagisawa S, Okamoto R, Nishimura M, Tsuchiya S, Miyazaki M: [A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis]. Gan To Kagaku Ryoho; 2009 Nov;36(11):1897-900
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A successful two-stage treatment with CDDP and CPT-11 for pancreatic neuroendocrine carcinoma with liver metastasis].
  • A 59-year-old man was diagnosed as having a pancreatic carcinoma with synchronous liver metastasis at initial surgery.
  • After wedge resection of liver tumor for histopathological analysis and gastro-jejunostomy, he was treated with 3 cycles of combined systematic chemotherapy consisting of CDDP and CPT-11, because of histopathological diagnosis confirming a neuroendocrine carcinoma of the pancreas.
  • After chemotherapy, there was no recurrence and the primary tumor was reduced in size.
  • Therefore, pancreatico-duodenectomy was performed as a curative treatment in two stages.
  • During the follow-up, the patient has been alive without any signs of recurrence for 20 months since the diagnosis.
  • Recently, several consecutive chemotherapies have been an effective modality to improve a poor prognosis for unresectable neuroendocrine carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Neuroendocrine / therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Combined Modality Therapy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19920396.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


6. Dadan J, Wojskowicz P, Wojskowicz A: Neuroendocrine tumors of the pancreas. Wiad Lek; 2008;61(1-3):43-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors of the pancreas.
  • The neuroendocrine tumors (NET) of the pancreas are very rare lesions with frequency of about 3 to 10 per 1 000 000 inhabitants.
  • The neuroendocrine tumors composes a heterogeneous group of tumors.
  • The most often NET of the pancreas are insulinoma, gastrinoma, glucagonoma, somatostatinoma, VIPoma.
  • There is a recommendation to assay hormonal activity, measure concentration of specific peptides, biogenic amines and hormones produced by NET cells to establish diagnosis.
  • Those tests are useful in monitoring treatment and in prognostication course of the disease.
  • Imaging methods especially useful in localization GEP-NET are: ultrasound (US), endoscopic ultrasound (EUS), somatostatin receptor scintigraphy (SRS), computer tomography (CT), magnetic resonance (MR) and angiography.
  • The most sensitive method in preoperative diagnosis seems to be EUS or less accessible intra ductal ultrasonography (IDUS).
  • Surgical treatment depends on progression of disease as well as on localization of tumor and consists in both radical methods and palliative operations.
  • The gold standard in pharmacological treatment are somatostatin analogs which can induce long-term remission even in inoperable lesions.
  • Although NET of pancreas are very rare. they are still important diagnostic and therapeutic problem and requires interdisciplinary co-operation.
  • The neuroendocrine tumors should be treated in centers with highest rank of references.
  • [MeSH-major] Carcinoma, Islet Cell / diagnosis. Carcinoma, Islet Cell / therapy. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Gastrinoma / diagnosis. Gastrinoma / metabolism. Gastrinoma / therapy. Glucagonoma / diagnosis. Glucagonoma / metabolism. Glucagonoma / therapy. Humans. Insulinoma / diagnosis. Insulinoma / metabolism. Insulinoma / therapy. Somatostatinoma / diagnosis. Somatostatinoma / metabolism. Somatostatinoma / therapy. Vipoma / diagnosis. Vipoma / metabolism. Vipoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18717042.001).
  • [ISSN] 0043-5147
  • [Journal-full-title] Wiadomości lekarskie (Warsaw, Poland : 1960)
  • [ISO-abbreviation] Wiad. Lek.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 30
  •  go-up   go-down


7. Schott M, Feldkamp J, Lettmann M, Simon D, Scherbaum WA, Seissler J: Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma. Clin Endocrinol (Oxf); 2001 Aug;55(2):271-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dendritic cell immunotherapy in a neuroendocrine pancreas carcinoma.
  • OBJECTIVE: Metastatic neuroendocrine carcinomas of the pancreas frequently fail to respond to conventional therapies, including radiation and chemotherapy.
  • We therefore tested a dendritic cell-based immunotherapy in an attempt to eradicate residual tumour masses in a patient suffering from a metastatic insulin-producing pancreatic carcinoma.
  • RESULTS: Three weeks after first treatment, the patient developed a strong delayed-type hypersensitivity (DTH) skin reaction with an erythema and induration after the challenge with TL-pulsed DCs, which indicates the efficient generation of antigen-specific memory T-cells.
  • Most strikingly, DC-based vaccination was accompanied by a steady decrease of the tumour marker chromogranin A from 2.93 umol/l initially to below the detection limit of 0.15 umol/l within 9 months of therapy.
  • CONCLUSIONS: Our data indicate that vaccination with tumour lysate-pulsed DCs induced a significant antitumour immune response in a neuroendocrine carcinoma of the pancreas.
  • This approach represents an alternative strategy for the treatment of advanced neuroendocrine carcinomas that are resistant to conventional therapy.
  • [MeSH-major] Dendritic Cells / immunology. Immunotherapy / methods. Neuroendocrine Tumors / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adult. Biomarkers, Tumor / blood. Cell Division. Chromogranin A. Chromogranins / blood. Dose-Response Relationship, Drug. Humans. Hypersensitivity, Delayed / etiology. Liver Neoplasms / immunology. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Pulse Therapy, Drug. T-Lymphocytes / drug effects. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11531937.001).
  • [ISSN] 0300-0664
  • [Journal-full-title] Clinical endocrinology
  • [ISO-abbreviation] Clin. Endocrinol. (Oxf)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chromogranin A; 0 / Chromogranins
  •  go-up   go-down


8. Abood GJ, Go A, Malhotra D, Shoup M: The surgical and systemic management of neuroendocrine tumors of the pancreas. Surg Clin North Am; 2009 Feb;89(1):249-66, x
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The surgical and systemic management of neuroendocrine tumors of the pancreas.
  • Neuroendocrine tumors of the pancreas comprise a class of rare tumors that can be associated with symptoms of hormone overproduction.
  • Five distinct clinical endocrinopathies are associated with neuroendocrine tumors; however, most of these tumors remain asymptomatic and follow an indolent course.
  • [MeSH-major] Carcinoma, Neuroendocrine / surgery. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Catheter Ablation. Chemoembolization, Therapeutic. Combined Modality Therapy. Dacarbazine / therapeutic use. Gastrinoma / diagnosis. Gastrinoma / drug therapy. Gastrinoma / surgery. Humans. Insulinoma / diagnosis. Insulinoma / surgery. Liver Neoplasms / secondary. Octreotide / therapeutic use. Somatostatin / analogs & derivatives. Vipoma / diagnosis. Vipoma / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186239.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 51110-01-1 / Somatostatin; 7GR28W0FJI / Dacarbazine; RWM8CCW8GP / Octreotide
  • [Number-of-references] 117
  •  go-up   go-down


9. Spigel DR, Hainsworth JD, Greco FA: Neuroendocrine carcinoma of unknown primary site. Semin Oncol; 2009 Feb;36(1):52-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine carcinoma of unknown primary site.
  • Neuroendocrine carcinomas of unknown primary site are uncommon, diverse tumors with variable clinical behavior, predicted by tumor grade or differentiation.
  • Most of these carcinomas probably arise from an occult/clinically undetectable primary site in one of several locations (bronchus, pancreas, stomach, colon, rectum and several other sites).
  • Patients with these tumors are a subset of unknown primary carcinoma with relatively favorable prognoses.
  • Targeted therapies may have a role in the treatment of low-grade tumors.
  • The high-grade or poorly differentiated carcinomas, including small cell and large cell neuroendocrine tumors, are rapidly growing and aggressive but responsive to platinum-based combination chemotherapy.
  • Poorly differentiated large cell neuroendocrine tumors, first reported in 1988, are usually not recognized by routine hematoxylin and eosin light microscopy but require immunohistochemical stains or electron microscopy for their diagnosis.
  • A review of cytotoxic chemotherapy for patients with high-grade neuroendocrine carcinomas, including a series of 99 patients, revealed an overall response rate of 70%, with a 20% complete response rate.
  • Tumor grade/differentiation currently is an important determinant of the management of these patients, and therapy in the future will be based on a more precise knowledge of the unique biology of these tumors.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Neoplasms, Unknown Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179188.001).
  • [ISSN] 0093-7754
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


10. Buxhofer V, Ruckser R, Kier P, Habertheuer KH, Zelenka P, Tatzreiter G, Dorner S, Vedovelli H, Sebesta C, Hinterberger W: [High dosage therapy with stem cell transplantation in neuroendocrine carcinoma]. Acta Med Austriaca Suppl; 2000;52:37-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High dosage therapy with stem cell transplantation in neuroendocrine carcinoma].
  • [Transliterated title] Hochdosistherapie mit Stammzelltransplantation beim neuroendokrinen Karzinom.
  • Neuroendocrine carcinoma and small-cell lung cancer (SCLC) are highly responsive to chemo- and radiotherapy.
  • At the 2nd department of medicine in the Donauspital, 4 pts. with neuroendocrine carcinomas of different primary sites underwent high-dose chemotherapy with autologous stem-cell transplantation (ASTx). Pt.
  • 1 suffered from neuroendocrine lung cancer, pt.
  • 2 from a small-cell carcinoma of the pancreas. Pt.
  • 4 presented with neuroendocrine carcinoma of the prostate.
  • After 4-6 cycles induction chemotherapy pts. were consolidated with 1 cycle of HDCht and ASTx.
  • He is still in CR with a disease-free survival of 23 month after ASTx and 30 month after diagnosis. Pt.
  • 1, 2 and 4 died from relapse 10, 16 and 5 month after ASTx and 16, 22 and 9 month after diagnosis. Pts. with neuroendocrine carcinomas might be suitable candidates for HDCht and ASTx.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Hematopoietic Stem Cell Transplantation. Lung Neoplasms / drug therapy. Neuroendocrine Tumors / drug therapy
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Humans. Male. Middle Aged. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11261277.001).
  • [ISSN] 0303-8181
  • [Journal-full-title] Acta medica Austriaca. Supplement
  • [ISO-abbreviation] Acta Med Austriaca Suppl
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


11. Oberg K, Eriksson B: Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol; 2005 Oct;19(5):753-81
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocrine tumours of the pancreas.
  • Some of the tumours may be part of multiple endocrine neoplasia type one (MEN-1) syndrome or von Hippel-Lindau (vHL) disease.
  • The biochemical diagnosis of EPT is based on hormones and amines released.
  • The location of endocrine tumours of the pancreas includes different techniques, from endoscopic investigations to scintigraphy (e.g. somatostatin receptor scintigraphy) and positron emission tomography.
  • The medical treatment of endocrine pancreatic tumours consists of chemotherapy, somatostatin analogues and alpha-interferon.
  • In future, therapy will be custom-made and based on current knowledge of tumour biology and molecular genetics.
  • [MeSH-major] Carcinoma, Neuroendocrine / drug therapy. Carcinoma, Neuroendocrine / pathology. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Female. Gastrinoma / drug therapy. Gastrinoma / epidemiology. Gastrinoma / pathology. Glucagonoma / drug therapy. Glucagonoma / epidemiology. Glucagonoma / pathology. Humans. Immunohistochemistry. Incidence. Insulinoma / drug therapy. Insulinoma / epidemiology. Insulinoma / pathology. Male. Molecular Biology. Neoplasm Staging. Prognosis. Risk Assessment. Somatostatinoma / drug therapy. Somatostatinoma / epidemiology. Somatostatinoma / pathology. Survival Rate. Treatment Outcome. Zollinger-Ellison Syndrome / drug therapy. Zollinger-Ellison Syndrome / epidemiology. Zollinger-Ellison Syndrome / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16253899.001).
  • [ISSN] 1521-6918
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 141
  •  go-up   go-down


12. Nishimori H, Takahashi S, Nagasaki E, Kobayashi T, Yokoyama M, Shinozaki E, Mishima Y, Terui Y, Chin K, Mizunuma N, Ito Y, Inamura K, Hatake K: [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify]. Gan To Kagaku Ryoho; 2005 May;32(5):671-3
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An autopsied case of metastatic endocrine carcinoma of the pancreas with primary site difficult to identify].
  • A 40-year-old man suffering from right cheek swelling was first diagnosed with ameloblastoma or anaplastic poorly-differentiated carcinoma of the head and neck region.
  • He received 2 courses of CDDP/TXT chemotherapy (cisplatin 75 mg/m2, docetaxel 80 mg/m2) and achieved a partial response, but his carcinoma of the pancreas recurred.
  • The autopsy revealed a pathological diagnosis of metastatic endocrine carcinoma of the pancreas.
  • This case was close to a cancer with an unknown primary (CUP) site, and several favorable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy.
  • Poorly-differentiated neuroendocrine carcinomas like this case are highly sensitive to chemotherapy, and a careful pathological diagnosis may clarify its sensitivity to chemotherapy and the prognosis.
  • [MeSH-major] Carcinoma / secondary. Neoplasms, Unknown Primary / pathology. Pancreatic Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Paclitaxel / administration & dosage. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918570.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Schütte K, Bornschein J, Kuester D, Wieners G, Malfertheiner P: [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head]. Med Klin (Munich); 2010 Apr;105(4):291-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fulminant duodenal bleeding as first manifestation of a neuroendocrine carcinoma of the pancreatic head].
  • In the further staging, there was evidence for a neuroendocrine carcinoma of the pancreatic head with infiltration of the duodenum and hepatic metastases.
  • Afterwards, the systemic therapy was changed to a palliative chemotherapy with streptozotocin and 5-fluorouracil due to local progression of the disease and a Ki-67 index of 4% in the primary tumor.
  • CONCLUSION: In about 0.7% of patients with neuroendocrine tumors, the lesion is located in the pancreas.
  • The therapy depends on the local spread and histological grading as well as symptoms of the patient.
  • Alternative therapies in the palliative situation are somatostatin analogs, a classic systemic chemotherapy, or locoregional interventional procedures.
  • [MeSH-major] Duodenum / pathology. Gastrointestinal Hemorrhage / etiology. Neuroendocrine Tumors / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Disease Progression. Endoscopy, Digestive System. Humans. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Male. Mesenteric Artery, Superior / pathology. Neoplasm Invasiveness. Neoplasm Staging. Palliative Care. Pancreatectomy

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuroendocrinology. 2004;80(6):394-424 [15838182.001]
  • [Cites] Virchows Arch. 2006 Oct;449(4):395-401 [16967267.001]
  • [Cites] Endocr Rev. 2004 Jun;25(3):458-511 [15180952.001]
  • [Cites] Endocr Pathol. 2003 Winter;14(4):293-301 [14739487.001]
  • [Cites] Endocr Relat Cancer. 2007 Jun;14(2):221-32 [17639039.001]
  • [Cites] J Clin Gastroenterol. 2006 Aug;40(7):572-82 [16917396.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Jul 25;99:442-4 [14430796.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):934-59 [12569593.001]
  • [Cites] Lancet Oncol. 2008 Jan;9(1):61-72 [18177818.001]
  • (PMID = 20455052.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


14. Oberg KC, Wells K, Seraj IM, Garberoglio CA, Akin MR: ACTH-secreting islet cell tumor of the pancreas presenting as bilateral ovarian tumors and Cushing's syndrome. Int J Gynecol Pathol; 2002 Jul;21(3):276-80
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACTH-secreting islet cell tumor of the pancreas presenting as bilateral ovarian tumors and Cushing's syndrome.
  • Imaging studies revealed bilateral ovarian masses and a solid and cystic mass within the pancreas.
  • Pathological examination revealed a neuroendocrine islet cell tumor of the pancreas with bilateral ovarian metastases.
  • The patient received postoperative chemotherapy and has been disease-free for 6 years.
  • To our knowledge, this is the first reported case of an ACTH-secreting pancreatic neuroendocrine tumor presenting as bilateral ovarian metastases.
  • [MeSH-major] Carcinoma / secondary. Carcinoma, Islet Cell / pathology. Ovarian Neoplasms / secondary. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Adrenocorticotropic Hormone / biosynthesis. Adult. Chromogranin A. Chromogranins / biosynthesis. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Cushing's Syndrome.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12068175.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Chromogranins; 9002-60-2 / Adrenocorticotropic Hormone
  •  go-up   go-down


15. Salih HR, Hartmann JT: [Neuro-endocrine tumors of the gastrointestinal tract: epidemiology, classification, prognosis, diagnosis and therapeutic modalities]. Praxis (Bern 1994); 2005 Feb 23;94(8):291-302
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuro-endocrine tumors of the gastrointestinal tract: epidemiology, classification, prognosis, diagnosis and therapeutic modalities].
  • [Transliterated title] Neuroendokrine Tumoren des Gastrointestinaltraktes.
  • The neuro-endocrine tumors of the gastrointestinal tract comprise a heterogeneous group of slow-growing malignancies with great differences regarding their localization, tissue of origin and their entopic and ectopic production of hormones.
  • They can be subdivided in carcinoid tumors and endocrine tumors of the pancreas.
  • Furthermore, the value of available diagnostic techniques and the role of different therapeutic modalities like surgery, radiation, biotherapy and cytostatic chemotherapy are discussed.
  • [MeSH-major] Carcinoma, Neuroendocrine / diagnosis. Gastrointestinal Neoplasms / diagnosis
  • [MeSH-minor] Carcinoid Tumor / diagnosis. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / therapy. Cross-Sectional Studies. Diagnosis, Differential. Humans. Neoplasm Staging. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / mortality. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / therapy. Paraneoplastic Endocrine Syndromes / diagnosis. Paraneoplastic Endocrine Syndromes / mortality. Paraneoplastic Endocrine Syndromes / pathology. Paraneoplastic Endocrine Syndromes / therapy. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779611.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


16. Bastian PJ, Eidt S, Koslowsky TC, Wulke AP, Siedek M: Duodenal somatostatinoma: clinical and immunohistochemical patterns--difficult differential diagnosis in regard to gangliocytic paraganglioma: report of a case. Eur J Med Res; 2005 Mar 29;10(3):135-8
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Duodenal somatostatinoma: clinical and immunohistochemical patterns--difficult differential diagnosis in regard to gangliocytic paraganglioma: report of a case.
  • A 8.5 cm globular mass in the area of the unicate process of the pancreas was detected in a 45 year old caucasian female by computerized tomography.
  • Initial treatment consisted of right pancreatectomy with preservation of the pylorus.
  • Histological evaluation rendered a diagnosis of low-grade malignant neuroendocrine carcinoma with expression of somatostatin, respectively of somatostatinoma arising in the duodenum and infiltrating into the pancreas.
  • Treatment of choice is radical surgical resection with a possible cure in early stages of the disease.
  • Additional chemotherapy and supportive care may be beneficial for the patient.
  • [MeSH-major] Duodenal Neoplasms / diagnosis. Paraganglioma / diagnosis. Somatostatinoma / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Somatostatinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851380.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


17. Grenacher L, Klauss M: [Computed tomography of pancreatic tumors]. Radiologe; 2009 Feb;49(2):107-23
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Computed tomography of pancreatic tumors].
  • Computed tomography (CT) and in particular multi-detector row computed tomography (MDCT), also known as multislice CT (MSCT), is ideally suited for detecting pancreatic tumors because of the high spatial resolution.The method of choice is hydro-CT which involves distension of the stomach and duodenum by administration of 1-1.5 l water as a negative contrast medium under medically induced hypotension by administration of buscopan.
  • The patient is laid on the right side at an angle of 30-45 degrees in order to obtain an artefact-free image of the close anatomical relationship around the pancreas head.
  • After the correct diagnosis of an adenocarcinoma has been made only 20% of all patients are shown to have a surgically resectable disease, but the overall survival rate is significantly higher after resection in combination with a multimodal tumor therapy strategy.
  • The reason is that the correct diagnosis of the resectability of the tumor is one of the main criteria for overall survival of these patients.
  • Currently practically all pancreatic tumors can be detected using MDCT and the detection rate varies between 70% and 100% (most recent literature references give a sensitivity of 89% and specificity up to 99%).
  • In some rare cases the differentiation between focal necrotizing pancreatitis and pancreatic carcinoma can be difficult even with sophisticated protocols.
  • MDCT is an ideal tool for the detection of neuroendocrine tumors, metastases and for the differentiation of cystic pancreatic lesions such as pseudocysts, microcystic adenomas or intraductal papillary mucinous neoplasms (IPMN).
  • Moreover MD-CT is an ideal procedure for the differentiation of local tumor stages in patients under neoadjuvant or adjuvant chemotherapy.
  • [MeSH-major] Image Processing, Computer-Assisted. Imaging, Three-Dimensional. Pancreatic Neoplasms / diagnostic imaging. Tomography, Spiral Computed
  • [MeSH-minor] Adenocarcinoma / diagnostic imaging. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / diagnostic imaging. Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / diagnostic imaging. Carcinoma, Pancreatic Ductal / mortality. Carcinoma, Pancreatic Ductal / pathology. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / diagnostic imaging. Carcinoma, Papillary / mortality. Carcinoma, Papillary / pathology. Carcinoma, Papillary / surgery. Diagnosis, Differential. Disease-Free Survival. Humans. Neuroendocrine Tumors / diagnostic imaging. Neuroendocrine Tumors / mortality. Neuroendocrine Tumors / pathology. Neuroendocrine Tumors / surgery. Pancreas / diagnostic imaging. Pancreas / pathology. Pancreatectomy. Pancreatic Pseudocyst / diagnostic imaging. Prognosis. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Radiol. 2006 Nov;79(947):880-7 [16822803.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Ann Surg. 2005 Sep;242(3):413-9; discussion 419-21 [16135927.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):393-405; discussion 405-7 [9351708.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] Pancreatology. 2008;8(3):236-51 [18497542.001]
  • [Cites] Radiologe. 2003 Apr;43(4):293-300 [12721645.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):438-45 [16012297.001]
  • [Cites] Pancreas. 2005 Apr;30(3):218-22 [15782097.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] N Engl J Med. 1992 Feb 13;326(7):455-65 [1732772.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Radiologe. 1998 Apr;38(4):279-86 [9622822.001]
  • [Cites] Radiographics. 2005 Nov-Dec;25(6):1471-84 [16284129.001]
  • [Cites] Eur Radiol. 2004 Jul;14 (7):1188-95 [15083335.001]
  • [Cites] Abdom Imaging. 2006 Sep-Oct;31(5):568-74 [16465578.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1709-18 [16550353.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Digestion. 2003;68(1):24-33 [12949436.001]
  • [Cites] J Comput Assist Tomogr. 2005 Mar-Apr;29(2):170-5 [15772532.001]
  • [Cites] Radiology. 2000 Jul;216(1):163-71 [10887243.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):149-56 [12541123.001]
  • [Cites] Radiologe. 2008 Aug;48(8):752-63 [18633589.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] AJR Am J Roentgenol. 1997 Aug;169(2):459-64 [9242754.001]
  • [Cites] Eur J Radiol. 2007 Jun;62(3):371-7 [17433598.001]
  • [Cites] Chirurg. 2003 Mar;74(3):202-7 [12647076.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Histopathology. 2008 Apr;52(5):539-51 [17903202.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Radiologe. 1996 May;36(5):397-405 [8778924.001]
  • [Cites] J Magn Reson Imaging. 2007 Jul;26(1):86-93 [17659551.001]
  • [Cites] Dtsch Med Wochenschr. 2007 Apr 13;132(15):813-7 [17427092.001]
  • [Cites] Arch Surg. 1998 Jan;133(1):61-5 [9438761.001]
  • [Cites] Ann Surg Oncol. 2006 Jan;13(1):75-85 [16372157.001]
  • [Cites] Pancreatology. 2008;8(2):199-203 [18434757.001]
  • [Cites] Radiology. 2006 Mar;238(3):912-9 [16439566.001]
  • [Cites] World J Surg. 2006 Aug;30(8):1553-9 [16773248.001]
  • [Cites] AJR Am J Roentgenol. 2003 Feb;180(2):475-80 [12540455.001]
  • [Cites] Pancreas. 2006 Aug;33(2):111-8 [16868475.001]
  • [Cites] JOP. 2007 Mar 10;8(2):214-22 [17356246.001]
  • [Cites] Pancreatology. 2008;8(2):135-41 [18382099.001]
  • [Cites] AJR Am J Roentgenol. 2003 May;180(5):1311-23 [12704043.001]
  • [Cites] Pancreatology. 2008;8(2):204-10 [18434758.001]
  • [Cites] Radiologe. 2006 May;46(5):421-37; quiz 438 [16715226.001]
  • [Cites] Rofo. 1998 Mar;168(3):211-6 [9551105.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] AJR Am J Roentgenol. 1990 Nov;155(5):995-6 [2120971.001]
  • [Cites] Surg Clin North Am. 1995 Oct;75(5):1001-16 [7660245.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] J Gastrointest Surg. 1999 May-Jun;3(3):233-43 [10481116.001]
  • [Cites] Eur Radiol. 2007 Mar;17(3):638-49 [17021700.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] AJR Am J Roentgenol. 2006 Dec;187(6):1513-20 [17114545.001]
  • [Cites] Pancreatology. 2009;9(5):621-30 [19657217.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Radiology. 1993 Mar;186(3):799-802 [8381551.001]
  • [Cites] Pancreatology. 2001;1(6):648-55 [12120249.001]
  • [Cites] J Gastrointest Surg. 1998 Sep-Oct;2(5):472-82 [9843608.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19137277.001).
  • [ISSN] 1432-2102
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 71
  •  go-up   go-down


18. Blaszyk H, Hartmann A, Bjornsson J: Cancer of unknown primary: clinicopathologic correlations. APMIS; 2003 Dec;111(12):1089-94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer of unknown primary origin (CUP) accounts for 5-10% of all malignant tumors at presentation and remains the death certificate diagnosis in 0.5-5% of patients.
  • We reviewed 9,436 consecutive autopsies performed between 1984 and 1999 at the Mayo Clinic, matched with 177,167 cancer patients treated in the same time period.
  • Antemortem pathologic diagnoses were obtained in 57 patients, agreed with postmortem diagnoses in 98%, and included adenocarcinoma (n=44), undifferentiated carcinoma (n=7), squamous cell carcinoma (n=3), and others (n=3).
  • Of 43 patients evaluated for tumor-specific therapy, only six received no further oncologic treatment and untreated patients survived a median of 57 (range 10-280) days, compared with 225 (range 19-1,129) days for patients treated with chemotherapy and/or radiotherapy (n=37).
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Neuroendocrine / secondary. Carcinoma, Squamous Cell / secondary. Neoplasms, Unknown Primary / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Autopsy. Biliary Tract / pathology. Biliary Tract Neoplasms / diagnosis. Cohort Studies. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Tract / pathology. Humans. Lung / pathology. Lung Neoplasms / diagnosis. Male. Middle Aged. Pancreas / pathology. Pancreatic Neoplasms / diagnosis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14678017.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


19. Kianmanesh R, O'toole D, Sauvanet A, Ruszniewski P, Belghiti J: [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors]. J Chir (Paris); 2005 May-Jun;142(3):132-49
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
  • [Transliterated title] Traitement chirurgical des tumeurs endocrines gastro-entéro-pancréatiques.
  • Endocrine tumors (ET) of the digestive tract (formerly called neuroendocrine tumors) are rare.
  • They are classified into two principal types: gastrointestinal ET's (formerly called carcinoid tumors) which are the most common, and pancreaticoduodenal ET's.
  • Poorly-differentiated ET's have a poor prognosis and are treated by chemotherapy.
  • Surgical excision is the only curative treatment of well-differentiated ET's.
  • The most common sites of gastrointestinal ET's ( carcinoids) are the appendix and the rectum; these are often small (<1 cm), benign, and discovered fortuitously at the time of appendectomy or colonoscopic removal.
  • They are usually malignant and of advanced stage at diagnosis presenting as a palpable or obstructing mass or as liver metastases.
  • Insulinoma and gastrinoma (cause of the Zollinger-Ellison syndrome) are the most common functional ET's. 80% are sporadic; in these cases, tumor size, location, and malignant potential determine the type of resection which may vary from a simple enucleation to a formal pancreatectomy.
  • In 10-20% of cases, pancreaticoduodenal ET presents in the setting of multiple endocrine neoplasia (NEM type I), an autosomal-dominant genetic disease with multifocal endocrine involvement of the pituitary, parathyroid, pancreas, and adrenal glands.
  • For insulinoma with NEM-I, enucleation of lesions in the pancreatic head plus a caudal pancreatectomy is the most appropriate procedure.
  • [MeSH-major] Carcinoid Tumor / surgery. Carcinoma, Islet Cell / surgery. Carcinoma, Neuroendocrine / surgery. Insulinoma / surgery. Intestinal Neoplasms / surgery. Multiple Endocrine Neoplasia Type 1 / surgery. Pancreatic Neoplasms / surgery. Stomach Neoplasms / surgery. Zollinger-Ellison Syndrome / surgery
  • [MeSH-minor] Adult. Gastrinoma / diagnosis. Gastrinoma / surgery. Glucagonoma / diagnosis. Glucagonoma / surgery. Humans. Liver Neoplasms / secondary. Lymphatic Metastasis. Malignant Carcinoid Syndrome / diagnosis. Malignant Carcinoid Syndrome / surgery. Multicenter Studies as Topic. Pancreatectomy. Postoperative Care. Postoperative Complications. Prognosis. Somatostatinoma / diagnosis. Somatostatinoma / surgery. Vipoma / diagnosis. Vipoma / surgery

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142076.001).
  • [ISSN] 0021-7697
  • [Journal-full-title] Journal de chirurgie
  • [ISO-abbreviation] J Chir (Paris)
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 236
  •  go-up   go-down


20. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA: Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer; 2003 Sep;39(14):1990-2005
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic and therapeutic management of cancer of an unknown primary.
  • Patients with CUP present with metastatic disease for which the site of origin cannot be identified at the time of diagnosis.
  • The following clinicopathological entities have been recognised: (i) metastatic CUP primarily to the liver or to multiple sites, (ii) metastatic CUP to lymph nodes including the sub-sets involving primarily the mediastinal-retroperitoneal, the axillary, the cervical or the inguinal nodes, (iii) metastatic CUP of peritoneal cavity including the peritoneal papillary serous carcinomatosis in females and the peritoneal non-papillary carcinomatosis in males or females, (iv) metastatic CUP to the lungs with parenchymal metastases or isolated malignant pleural effusion, (v) metastatic CUP to the bones, (vi) metastatic CUP to the brain, (vii) metastatic neuroendocrine carcinomas and (viii) metastatic melanoma of an unknown primary.
  • Extensive work-up with specific pathology investigations (immunohistochemistry, electron microscopy, molecular diagnosis) and modern imaging technology (computed tomography (CT), mammography, Positron Emission Tomography (PET) scan) have resulted in some improvements in diagnosis; however, the primary site remains unknown in most patients, even on autopsy.
  • The most frequently detected primaries are carcinomas hidden in the lung or pancreas.
  • Several favourable sub-sets of CUP have been identified, which are responsive to systemic chemotherapy and/or locoregional treatment.
  • Identification and treatment of these patients is of paramount importance.
  • The considered responsive sub-sets to platinum-based chemotherapy are the poorly differentiated carcinomas involving the mediastinal-retroperitoneal nodes, the peritoneal papillary serous adenocarcinomatosis in females and the poorly differentiated neuroendocrine carcinomas.
  • Other tumours successfully managed by locoregional treatment with surgery and/or irradiation are the metastatic adenocarcinoma of isolated axillary nodes, metastatic squamous cell carcinoma of cervical nodes, or any other single metastatic site.
  • Empirical chemotherapy benefits some of the patients who do not fit into any favourable sub-set, and should be considered in patients with a good performance status.
  • [MeSH-major] Neoplasms, Unknown Primary / diagnosis. Neoplasms, Unknown Primary / therapy
  • [MeSH-minor] Diagnostic Imaging / methods. Female. Humans. Lymphatic Metastasis / diagnosis. Male. Physician's Role. Prognosis. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cancer. 2004 Jun;40(9):1454-5 [15177507.001]
  • (PMID = 12957453.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 119
  •  go-up   go-down


21. Schmitt J, Boullu-Sanchis S, Moreau F, Drui S, Louis B, Chabrier G, Pinget M, Jeandidier N: Association of malignant insulinoma and type 2 diabetes mellitus: a case report. Ann Endocrinol (Paris); 2008 Feb;69(1):69-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of malignant insulinoma and type 2 diabetes mellitus: a case report.
  • We report a case of recurrent hypoglycemia due to malignant insulinoma in a type 2 diabetic patient correctly controlled for years with the same doses of oral antidiabetic agents.
  • She had a history of type 2 diabetes since 2000.
  • Severe hypoglycemia continued despite interrupting diabetes medications.
  • CT scan showed "cystic" nodes in the pancreas and in the liver.
  • Liver biopsy found a well-differentiated neuroendocrine carcinoma with positive staining for chromogranin A and negative staining for insulin.
  • Malignant insulinoma survival is less than two years, shorter when hepatic localizations are present at diagnosis.
  • Association of diabetes with insulinoma delays the diagnosis, but does not alter prognosis or favor carcinoma frequency.
  • [MeSH-major] Diabetes Mellitus, Type 2 / complications. Insulinoma / complications
  • [MeSH-minor] Aged. Antihypertensive Agents / therapeutic use. Creatinine / blood. Diabetic Angiopathies / drug therapy. Female. Hemoglobin A, Glycosylated / metabolism. Humans. Hypertension / drug therapy. Hypoglycemia / etiology. Insulin / blood. Tomography, X-Ray Computed


22. Schütt M, Lorch H, Krüger S, Klingenberg RD, Peters A, Klein HH: [Recurrent hypoglycemia caused by malignant insulinoma: chemoembolization as a therapeutic option]. Med Klin (Munich); 2001 Oct 15;96(10):632-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrent hypoglycemia caused by malignant insulinoma: chemoembolization as a therapeutic option].
  • Ultrasound and computertomography of the abdomen showed a huge inhomogeneous mass in the tail of pancreas and multiple lesions in the liver, respectively.
  • Core needle biopsies revealed typical histopathological findings of a neuroendocrine carcinoma.
  • TREATMENT AND COURSE: Eight cycles of chemotherapy were given using streptozotocin/doxorubicin for three cycles and streptozotocin/5-fluorouracil for the remaining therapy over a period of 16 months resulting in a reduction in size of liver metastases and improvement of symptoms.
  • Following 6 months without any therapy new episodes of severe hypoglycemia and progression of the liver metastases occurred.
  • Despite seven further cycles of chemotherapy and additional treatment with diazoxide/octreotide the patient remained hypoglycemic and continuous glucose infusions became necessary.
  • CONCLUSION: Chemoembolization is an effective possibility in the palliative treatment of advanced malignant insulinoma.
  • [MeSH-major] Chemoembolization, Therapeutic. Hypoglycemia / etiology. Insulinoma / therapy. Liver Neoplasms / therapy. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Female. Humans. Recurrence






Advertisement